Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
about
Natural rewards, neuroplasticity, and non-drug addictionsNaltrexone for cocaine dependence treatmentNaltrexone for cocaine dependence treatmentChronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapseThe neurobiology and genetics of impulse control disorders: relationships to drug addictionsEvidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intakeGDNF is a fast-acting potent inhibitor of alcohol consumption and relapseContributions of the paraventricular thalamic nucleus in the regulation of stress, motivation, and moodSodium oxybate in the treatment of binge eating disorder: an open-label, prospective studyHeroin self-administration: II. CNS gene expression following withdrawal and cue-induced drug-seeking behaviorPersistent alterations in mesolimbic gene expression with abstinence from cocaine self-administrationUp-regulation of AGS3 during morphine withdrawal promotes cAMP superactivation via adenylyl cyclase 5 and 7 in rat nucleus accumbens/striatal neuronsA unified framework for addiction: vulnerabilities in the decision processStress-Induced Reinstatement of Drug Seeking: 20 Years of Progress.Aerobic exercise attenuates reinstatement of cocaine-seeking behavior and associated neuroadaptations in the prefrontal cortex.Social dominance in female monkeys: dopamine receptor function and cocaine reinforcement.DSM-5 criteria for substance use disorders: recommendations and rationaleRelaxin-3/RXFP3 system regulates alcohol-seeking.How does stress lead to risk of alcohol relapse?Cocaine-induced reinstatement during limited and extended drug access conditions in rhesus monkeys.Abuse liability assessment of tobacco products including potential reduced exposure productsPharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Brain imaging studies in pathological gambling.The clinical significance of drug cravingRepeated episodes of heroin cause enduring alterations of circadian activity in protracted abstinence.The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials.Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sectorEffects of chronic administration of drugs of abuse on impulsive choice (delay discounting) in animal models.Identifying the neural circuitry of alcohol craving and relapse vulnerability.Inhibition of morphine-induced cAMP overshoot: a cell-based assay model in a high-throughput format.Prolonged duration of craving, mood, and autonomic responses elicited by cues and imagery in smokers: Effects of tobacco deprivation and sex.Orphanin FQ/nociceptin not only blocks but also reverses behavioral adaptive changes induced by repeated cocaine in miceCocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack-cocaine dependence in the NetherlandsReversal of cocaine addiction by environmental enrichment.Alcohol craving in adolescents: bridging the laboratory and natural environmentPavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine.Performance of a craving criterion in DSM alcohol use disorders.Drugs and addiction: an introduction to epigenetics.Current pharmacotherapy options for bulimia nervosa and binge eating disorder.
P2860
Q22251254-CD0C92B9-2E90-4FD8-8E96-B9AD22DF254CQ24188333-5EA99100-D0C8-4944-AD83-5ED3A03C9F4BQ24234664-40F514F8-5659-4CF3-886B-CDBA10E7D705Q24633835-71109F41-603D-4396-908A-73C2D2D3496CQ24642641-D3F31CCC-6516-48F8-9429-C46ED188AAE5Q24651508-2E81ABB3-E2F3-4FFA-A2DC-B41ED2FE7E42Q24658003-5D0899B9-84EA-4422-AC3F-7726562E4742Q27026360-8409569C-7AF9-488D-9169-652DA4236567Q28275217-C73381C9-080E-4A06-9055-133306A56F56Q28386419-BEFADF00-934B-48A9-9BCC-46433C130E80Q28393231-4111DAB1-A969-4C72-AA14-311D1B510932Q28577675-01FFF050-C048-4E67-9418-0CB8167A104AQ28680729-EBD42BC4-64AB-43BC-AF50-D64BE7F7758CQ30366964-A54C062E-F222-4710-B57F-1A969209223AQ30430285-84B47DB1-1E54-488F-9F07-56C885DE72AAQ30521285-74FB17E4-0E27-4B50-A2BE-08C61061767CQ30544314-E29F9D9D-0E0E-4CDB-8C5B-69CF60228DB9Q30560386-484B3162-96CC-410D-8A9C-6FC367A1672DQ30616221-E6C160B8-74D3-4F18-B411-F686A17A9AF4Q33552551-518DF291-D953-4B5A-8E0C-1836D9FEEB89Q33559301-D2E08082-2BA2-4455-A64E-6EE7A99AEDBBQ33582063-1C7F27A1-876B-4486-BAD9-1A81AE85EC3EQ33598487-7E4FFFA9-F492-48E4-8FB0-DC0A702A5990Q33646993-6A3046D3-F729-48A1-BC96-9DF876CD6E9AQ33696808-F2AAF4AD-0057-4F3B-9EEC-0146691CBED7Q33771947-A9447C2F-5984-445D-9E68-A698D2B9AEB8Q33776083-55F8D66C-3300-4FFF-A935-49B0E5760EDCQ33810987-4AC66428-A1EA-4D52-9DED-85F67240938AQ33869692-1786F855-2FB5-4A94-AABE-B13D5E9EB8A0Q33887107-41F433FE-06E9-420B-AFEF-CFB69CA79E5DQ33906783-487A48D4-F1C6-4DB1-B864-1C0B2E6B3718Q33957942-8C15B3A6-8D45-4929-A5A1-9F758AE45125Q33959588-E275E0B8-F543-4DDC-B926-1BFE69F8862CQ33997733-44192E08-A00B-449C-AED4-573799B5228CQ34014401-6B1B438F-6AEC-4518-9C7C-AAE26D23CD3BQ34024477-80ABEB3E-F922-457F-AF6D-907662B3EB45Q34060576-39DD6674-CBEE-4340-A8A2-0479E553D210Q34091545-F8503E25-F09D-48E8-BC85-32BBB819FBD7Q34157414-BF406006-C605-473A-99CB-40324D380CBFQ34297444-13644875-04A4-4E4B-9686-D59697D597E1
P2860
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Anticraving medications for re ...... s of psychoactive medications.
@ast
Anticraving medications for re ...... s of psychoactive medications.
@en
type
label
Anticraving medications for re ...... s of psychoactive medications.
@ast
Anticraving medications for re ...... s of psychoactive medications.
@en
prefLabel
Anticraving medications for re ...... s of psychoactive medications.
@ast
Anticraving medications for re ...... s of psychoactive medications.
@en
P1476
Anticraving medications for re ...... s of psychoactive medications.
@en
P2093
Charles P O'Brien
P304
P356
10.1176/APPI.AJP.162.8.1423
P407
P577
2005-08-01T00:00:00Z